Decorative Decorative

News Releases

NEMUS Bioscience CEO to Present at BIO CEO & Investor Conference

Presentation to Take Place on Tuesday, February 9, 2016 at 10:30AM EST

COSTA MESA, CA -- (Marketwired) -- 02/02/16 -- NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, announces that Brian Murphy, MD, NEMUS Bioscience's CEO and CMO, will present at the BIO CEO & Investor Conference in New York City. The conference will be held February 8-9, 2016 at the Waldorf Astoria New York Hotel.


DATE: Tuesday, February 9, 2016

TIME: 10:30 AM EST

LOCATION: Waldorf Astoria - Louis XVI

The BIO CEO & Investor Conference is one of the largest investor conferences focused on bringing together emerging publicly traded and select private biotech, investors, and industry analysts who influence the future landscape of the biotechnology industry. Additional information can be found at:

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits of cannabinoid-based medicine and the timing of our near term, intermediate term and long term goals. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

PCG Advisory Group

Investor Relations
Adam Holdsworth
Phone: 646-862-4607

Media Relations
Sean Leous
Phone: 646-863-8998

Source: NEMUS Bioscience, Inc.